Ack1 promoted the activation of Toll-like receptors (TLRs) in macrophages, and the Ack1 inhibitor AIM-100 mitigated the lupus symptoms of mice treated with a TLR7 ligand [23]. This evidence concerns the gene TLR7 and systemic lupus erythematosus.